

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	10	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	11	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	12	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	13	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	14	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	15	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	16	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	17	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	18	JUL 28	EPFULL enhanced with additional legal status information from the EPOline Register
NEWS	19	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	20	JUL 28	STN Viewer performance improved
NEWS	21	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	22	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	23	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	24	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	25	AUG 25	CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS	26	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008

=> s thrombomodulin and (PEG)
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file medline, uspatful, dgene, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 15:18:37 ON 15 SEP 2008

FILE 'USPATFULL' ENTERED AT 15:18:37 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:18:37 ON 15 SEP 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008
Copyright (c) 2008 The Thomson Corporation

=> s thrombomodulin and polymer
L1 824 THROMBOMODULIN AND POLYMER

=> s (truncated thrombomodulin conjugate)
L2 0 (TRUNCATED THROMBOMODULIN CONJUGATE)

=> s l1 and (conjugate thrombomodulin)
L3 0 L1 AND (CONJUGATE THROMBOMODULIN)

=> s (thrombomodulin conjugate)
L4 1 (THROMBOMODULIN CONJUGATE)

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 1 USPATFULL on STN
TI Thrombomodulin Derivatives and Conjugates
AB The transmembrane human protein thrombomodulin (TM), as a critical regulator of the protein C pathway, represents the major anticoagulant mechanism that is operative in both normal and injured blood vessels under physiologic conditions in vivo. Compositions and methods are disclosed relating to thrombomodulin derivatives and conjugates,

including methods for site-specific pegylation and compositions of a truncated thrombomodulin derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:58717 USPATFULL
TITLE: Thrombomodulin Derivatives and Conjugates
INVENTOR(S): Chaikof, Elliot L., Atlanta, GA, UNITED STATES
Cazalis, Chrystelle S., Pessac, FRANCE
Haller, Carolyn A., Atlanta, GA, UNITED STATES
PATENT ASSIGNEE(S): EMORY UNIVERSITY, Atlanta, GA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080051562	A1	20080228
APPLICATION INFO.:	US 2005-598149	A1	20050222 (10)
	WO 2005-US5554		20050222
			20070417 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-546436P	20040220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 4875 PEARL EAST CIRCLE, SUITE 200, BOULDER, CO, 80301, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008

L1 824 S THROMBOMODULIN AND POLYMER
L2 0 S (TRUNCATED THROMBOMODULIN CONJUGATE)
L3 0 S L1 AND (CONJUGATE THROMBOMODULIN)
L4 1 S (THROMBOMODULIN CONJUGATE)

=> s (polyacrylamide and poly(t-butyl acrylate))

MISSING OPERATOR 'POLY(T-BUTYL'

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s (carboxy terminus)

L5 29925 (CARBOXY TERMINUS)

=> file biosis, embase, uspatful, wpids, biotechds, medline, scisearch
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 28.62 29.04

FILE 'BIOSIS' ENTERED AT 15:32:57 ON 15 SEP 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:32:57 ON 15 SEP 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:32:57 ON 15 SEP 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:32:57 ON 15 SEP 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'BIOTECHDS' ENTERED AT 15:32:57 ON 15 SEP 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'MEDLINE' ENTERED AT 15:32:57 ON 15 SEP 2008

FILE 'SCISEARCH' ENTERED AT 15:32:57 ON 15 SEP 2008
Copyright (c) 2008 The Thomson Corporation

=> e haller, c/au

E1	1	HALLER Y I/AU
E2	2	HALLER YEO J/AU
E3	0 -->	HALLER, C/AU
E4	1	HALLERA E E/AU
E5	1	HALLERAK B/AU
E6	1	HALLERAKER/AU
E7	34	HALLERAKER B/AU
E8	4	HALLERAKER J/AU
E9	25	HALLERAKER J H/AU
E10	1	HALLERAKER J M/AU
E11	10	HALLERAKER JO H/AU
E12	1	HALLERAKER JON MORTEN/AU

=> e cazalis, c/au

E1	1	CAZALIS ROLLAND/AU
E2	1	CAZALIS ROMAIN NICOLAS/AU
E3	0 -->	CAZALIS, C/AU
E4	1	CAZALLA A A/AU
E5	2	CAZALLA BENEDICTO F/AU
E6	15	CAZALLA D/AU
E7	14	CAZALLA DEMIAN/AU
E8	1	CAZALLA FATIMA/AU
E9	1	CAZALLA FONCUEVA ANA MARIA/AU
E10	1	CAZALLA J B/AU
E11	1	CAZALLA L F/AU
E12	10	CAZALLA O/AU

=> e chaikof, e/au

E1	1	CHAIKOF M K/AU
E2	1	CHAIKOF V S/AU
E3	0 -->	CHAIKOF, E/AU
E4	2	CHAIKOFF E/AU
E5	2	CHAIKOFF ELLIOT/AU
E6	1	CHAIKOFF I C/AU
E7	2	CHAIKOFF I I/AU
E8	769	CHAIKOFF I L/AU
E9	10	CHAIKOFF L L/AU
E10	4	CHAIKOFF R/AU
E11	1	CHAIKOFF R H/AU
E12	1	CHAIKOFF RONALD/AU

=> d his

(FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008

L1 824 S THROMBOMODULIN AND POLYMER
L2 0 S (TRUNCATED THROMBOMODULIN CONJUGATE)
L3 0 S L1 AND (CONJUGATE THROMBOMODULIN)
L4 1 S (THROMBOMODULIN CONJUGATE)
L5 29925 S (CARBOXY TERMINUS)

FILE 'BIOSIS, EMBASE, USPATFULL, WPIDS, BIOTECHDS, MEDLINE, SCISEARCH' ENTERED AT 15:32:57 ON 15 SEP 2008

E HALLER, C/AU
E CAZALIS, C/AU
E CHAIKOF, E/AU

=> s (thromobomodulin and PEG)
L6 0 (THROMOBOMODULIN AND PEG)

=> s (thrombomodulin and pegylated)
L7 208 (THROMBOMODULIN AND PEGYLATED)

=> s l7 and (GGM)
L8 1 L7 AND (GGM)

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 1 USPATFULL on STN
TI Thrombomodulin Derivatives and Conjugates
AB The transmembrane human protein thrombomodulin (TM), as a critical regulator of the protein C pathway, represents the major anticoagulant mechanism that is operative in both normal and injured blood vessels under physiologic conditions in vivo. Compositions and methods are disclosed relating to thrombomodulin derivatives and conjugates, including methods for site-specific pegylation and compositions of a truncated thrombomodulin derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:58717 USPATFULL
TITLE: Thrombomodulin Derivatives and Conjugates
INVENTOR(S): Chaikof, Elliot L., Atlanta, GA, UNITED STATES
Cazalis, Chrystelle S., Pessac, FRANCE
Haller, Carolyn A., Atlanta, GA, UNITED STATES
PATENT ASSIGNEE(S): EMORY UNIVERSITY, Atlanta, GA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080051562	A1	20080228
APPLICATION INFO.:	US 2005-598149	A1	20050222 (10)
	WO 2005-US5554		20050222
			20070417 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-546436P	20040220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 4875 PEARL EAST CIRCLE, SUITE 200, BOULDER, CO, 80301, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008

L1 824 S THROMBOMODULIN AND POLYMER
L2 0 S (TRUNCATED THROMBOMODULIN CONJUGATE)
L3 0 S L1 AND (CONJUGATE THROMBOMODULIN)
L4 1 S (THROMBOMODULIN CONJUGATE)
L5 29925 S (CARBOXY TERMINUS)

FILE 'BIOSIS, EMBASE, USPATFULL, WPIDS, BIOTECHDS, MEDLINE, SCISEARCH' ENTERED AT 15:32:57 ON 15 SEP 2008

E HALLER, C/AU
E CAZALIS, C/AU
E CHAIKOF, E/AU
L6 0 S (THROMOBOMODULIN AND PEG)
L7 208 S (THROMBOMODULIN AND PEGYLATED)
L8 1 S L7 AND (GGM)

=> s l7 and (EGF4-6)

L9 1 L7 AND (EGF4-6)

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 1 USPATFULL on STN

TI Thrombomodulin Derivatives and Conjugates

AB The transmembrane human protein thrombomodulin (TM), as a critical regulator of the protein C pathway, represents the major anticoagulant mechanism that is operative in both normal and injured blood vessels under physiologic conditions in vivo. Compositions and methods are disclosed relating to thrombomodulin derivatives and conjugates, including methods for site-specific pegylation and compositions of a truncated thrombomodulin derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:58717 USPATFULL

TITLE: Thrombomodulin Derivatives and Conjugates

INVENTOR(S): Chaikof, Elliot L., Atlanta, GA, UNITED STATES

Cazalis, Chrystelle S., Pessac, FRANCE

Haller, Carolyn A., Atlanta, GA, UNITED STATES

PATENT ASSIGNEE(S): EMORY UNIVERSITY, Atlanta, GA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20080051562	A1	20080228	
APPLICATION INFO.:	US 2005-598149	A1	20050222	(10)
	WO 2005-US5554		20050222	
			20070417	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-546436P	20040220 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GREENLEE WINNER AND SULLIVAN P C, 4875 PEARL EAST
CIRCLE, SUITE 200, BOULDER, CO, 80301, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008

L1 824 S THROMBOMODULIN AND POLYMER
L2 0 S (TRUNCATED THROMBOMODULIN CONJUGATE)
L3 0 S L1 AND (CONJUGATE THROMBOMODULIN)
L4 1 S (THROMBOMODULIN CONJUGATE)
L5 29925 S (CARBOXY TERMINUS)

FILE 'BIOSIS, EMBASE, USPATFULL, WPIDS, BIOTECHDS, MEDLINE, SCISEARCH'
ENTERED AT 15:32:57 ON 15 SEP 2008

E HALLER, C/AU
E CAZALIS, C/AU
E CHAIKOF, E/AU
L6 0 S (THROMOBOMODULIN AND PEG)
L7 208 S (THROMBOMODULIN AND PEGYLATED)
L8 1 S L7 AND (GGM)
L9 1 S L7 AND (EGF4-6)

=> d l7 ti abs ibib 1-15

L7 ANSWER 1 OF 208 USPATFULL on STN
TI Compositions and methods for intraocular delivery of fibronectin
scaffold domain proteins
AB The present disclosure relates to novel sustained-release intraocular
drug delivery systems and improvements in the treatment of
retinopathies. In particular, fibronectin scaffold domain proteins that
selectively inhibit VEGFR-2 are contemplated.

ACCESSION NUMBER: 2008:252793 USPATFULL
TITLE: Compositions and methods for intraocular delivery of
fibronectin scaffold domain proteins
INVENTOR(S): Chen, Yan, Lexington, MA, UNITED STATES
Getmanova, Elena, Lexington, MA, UNITED STATES
Wright, Martin C., Boston, MA, UNITED STATES
Harris, Alan S., Andover, MA, UNITED STATES
Lim, Ai Ching, Newton, MA, UNITED STATES
Gokemeijer, Jochem, Arlington, MA, UNITED STATES
Sun, Lin, West Roxbury, MA, UNITED STATES
Wittekind, Michael, Bainbridge Island, WA, UNITED
STATES
PATENT ASSIGNEE(S): Adnexus, A Bristol-Myers Squibb R&D Company, Waltham,
MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080220049	A1	20080911
APPLICATION INFO.:	US 2007-894045	A1	20070817 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2006-448171, filed on 5 Jun 2006, PENDING Continuation of Ser. No. US 2005-101954, filed on 7 Apr 2005, ABANDONED Continuation of Ser. No. WO 2004-US40885, filed on 6 Dec 2004, PENDING

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2003-527886P	20031205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	11766	

L7 ANSWER 2 OF 208 USPATFULL on STN

TI Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2008:245953 USPATFULL

TITLE: Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof

INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Ringoes, NJ, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Gaithersburg, MD, UNITED STATES
Hawken, Donald R., Trenton, NJ, UNITED STATES

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20080213918	A1	20080904
APPLICATION INFO.:	US 2007-891836	A1	20070813 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-70456, filed on 2 Mar 2005, Pat. No. US 7345148 Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, Pat. No. US 7049096		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-283145P	20010411 (60)
	US 2001-283161P	20010411 (60)
	US 2001-288468P	20010503 (60)
	US 2001-300619P	20010625 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT
 DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1-20
 NUMBER OF DRAWINGS: 36 Drawing Page(s)
 LINE COUNT: 19843

L7 ANSWER 3 OF 208 USPATFULL on STN

TI Polymer Conjugates of K-252A and Derivatives Thereof

AB The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system. In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I).

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:220622 USPATFULL

TITLE: Polymer Conjugates of K-252A and Derivatives Thereof

INVENTOR(S): Traversa, Silvio, Palazzo Canavese (Torino), ITALY
 Bagnod, Raffaella, Bollengo (Torino), ITALY
 Barone, Domenico, Torino, ITALY
 Bertarione Rava Rossa, Luisa, Pavone Canavese (Torino), ITALY
 Fumero, Silvano, Ivrea (Torino), ITALY
 Mainero, Valentina, Ivrea (Torino), ITALY
 Marconi, Alessandra, Reggio Emilia, ITALY
 Oderda, Cecilia, Vesenaz, SWITZERLAND
 Pincelli, Carlo, Sassuolo (Modena), ITALY
 Lorenzetto, Chiara, Villafranca Piemonte (TO), ITALY
 Beccaria, Luca, Ivrea (TO), ITALY
 PATENT ASSIGNEE(S): CREABILIS THERAPEUTICS S.P.A., Colletterto Giacosa, ITALY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080193517	A1	20080814
APPLICATION INFO.:	US 2006-64461	A1	20060825 (12)
	WO 2006-EP8374		20060825
			20080222 PCT 371 date

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2005-710890P 20050825 (60)
 US 2005-720454P 20050927 (60)
 US 2006-811469P 20060607 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: ROTHWELL, FIGG, ERNST & MANBECK, P.C., 1425 K STREET,
 N.W., SUITE 800, WASHINGTON, DC, 20005, US

NUMBER OF CLAIMS: 36
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 19 Drawing Page(s)
 LINE COUNT: 1787
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 208 USPATFULL on STN
 TI Methods For Treating Bleeding
 AB Methods for the treatment of various bleeding disorders using variants
 of human Factor VII (hFVII) or activated FVII (FVIIa) having an altered
 activity compared to 5 recombinant FVIIa with the native human sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2008:214730 USPATFULL
 TITLE: Methods For Treating Bleeding
 INVENTOR(S): Ropke, Mads, Hellerup, DENMARK
 Lathrop, Stephanie J., Mountain View, CA, UNITED STATES
 PATENT ASSIGNEE(S): MAXYGEN HOLDINGS LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080188400	A1	20080807
APPLICATION INFO.:	US 2006-912484	A1	20060425 (11)
	WO 2006-DK50016		20060425
			20071024 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-674815P	20050426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, REDWOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1855	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 5 OF 208 USPATFULL on STN
 TI Highly Branched Hk Peptides as Effective Carriers of Sirna
 AB The present invention is directed to methods of transfecting cells with
 siRNA, by contacting a transfection complex with one or more cells,
 where the transfection complex includes a transport polymer and siRNA.
 The transport polymer may include for example, H.sup.3K8b and/or
 structurally similar compounds. The invention is also directed to such
 transfection complexes, and to compositions that include such
 transfection complexes. The invention is further directed to methods of
 treating patients using the transfection complexes of the present
 invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2008:195372 USPATFULL
 TITLE: Highly Branched Hk Peptides as Effective Carriers of

Sirna
INVENTOR(S): Mixson, Archibald, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080171025	A1	20080717
APPLICATION INFO.:	US 2005-718342	A1	20051117 (11)
	WO 2005-US41785		20051117
			20070501 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-628341P	20041117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CASTELLANO PLLC, P.O. Box 1555, Great Falls, VA, 22066, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1511	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 208 USPATFULL on STN
TI Modified coagulation factor IX polypeptides and use thereof for treatment
AB Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2008:117426 USPATFULL
TITLE: Modified coagulation factor IX polypeptides and use thereof for treatment
INVENTOR(S): Oyhenart, Jorge, La Pampa, ARGENTINA
Gallet, Xavier, Champhol, FRANCE
Borrelly, Gilles, Combs La Ville, FRANCE
Guyon, Thierry, Palaiseau, FRANCE
Vega, Manuel, Vigneux-sur-Seine, FRANCE
Drittanti, Lila, Vigneux-sur-Seine, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080102115	A1	20080501
APPLICATION INFO.:	US 2007-818985	A1	20070615 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-815113P	20060619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON, PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	130	
EXEMPLARY CLAIM:	1	
LINE COUNT:	10230	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 208 USPATFULL on STN

TI Polymers for functional particles
 AB The present invention generally relates to polymers and macromolecules, in particular, to block polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. The moiety, in some embodiments, may have a molecular weight greater than about 1000 Da; for example, the moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may also be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety. Another aspect of the invention is directed to systems and methods of producing such polymeric conjugates. In some embodiments, a solution containing a polymer is contacted with a liquid, such as an immiscible liquid, to form nanoparticles containing the polymeric conjugate. Other aspects of the invention are directed to methods using such libraries, methods of using or administering such polymeric conjugates, methods of promoting the use of such polymeric conjugates, kits involving such polymeric conjugates, or the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:92817 USPATFULL
 TITLE: Polymers for functional particles
 INVENTOR(S): Gu, Frank X., Cambridge, MA, UNITED STATES
 Teply, Benjamin A., Omaha, NE, UNITED STATES
 Langer, Robert S., Newton, MA, UNITED STATES
 Farokhzad, Omid C., Chestnut Hill, MA, UNITED STATES
 PATENT ASSIGNEE(S): Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
 The Brigham & Women's Hospital, Inc., Boston, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080081074	A1	20080403
APPLICATION INFO.:	US 2007-803843	A1	20070515 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-747240P	20060515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	2739	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 208 USPATFULL on STN

TI Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof
 AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic

methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:73063 USPTFULL
TITLE: Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Ringoes, NJ, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Gaithersburg, MD, UNITED STATES
Hawken, Donald R., Trenton, NJ, UNITED STATES
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080064094	A1	20080313
APPLICATION INFO.:	US 2007-890963	A1	20070808 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-70456, filed on 2 Mar 2005, PENDING Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, GRANTED, Pat. No. US 7049096		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283145P	20010411 (60)
	US 2001-283161P	20010411 (60)
	US 2001-288468P	20010503 (60)
	US 2001-300619P	20010625 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1-20	
NUMBER OF DRAWINGS:	36 Drawing Page(s)	
LINE COUNT:	19967	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 208 USPTFULL on STN

TI Glycosylation-Disrupted Factor VII Variants

AB The present invention relates to human coagulation Factor VII polypeptides, as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions comprising Factor VII polypeptides, uses and methods of treatment; and any additional inventive features related thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:66335 USPTFULL
TITLE: Glycosylation-Disrupted Factor VII Variants
INVENTOR(S): Bolt, Gert, Vaerloose, DENMARK
Steenstrup, Thomas Dock, Gentofte, DENMARK
Kristensen, Claus, Bronshoj, DENMARK

PATENT ASSIGNEE(S): Novo Nordisk HealthCare A/G, Zurich, SWITZERLAND,
CH-8050 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080058255	A1	20080306
APPLICATION INFO.:	US 2005-629926	A1	20050617 (11)
	WO 2005-EP52834		20050617
			20070928 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-967	20040621
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NOVO NORDISK, INC., PATENT DEPARTMENT, 100 COLLEGE ROAD WEST, PRINCETON, NJ, 08540, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1305	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 208 USPATFULL on STN
TI Thrombomodulin Derivatives and Conjugates
AB The transmembrane human protein thrombomodulin (TM), as a
critical regulator of the protein C pathway, represents the major
anticoagulant mechanism that is operative in both normal and injured
blood vessels under physiologic conditions in vivo. Compositions and
methods are disclosed relating to thrombomodulin derivatives
and conjugates, including methods for site-specific pegylation and
compositions of a truncated thrombomodulin derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2008:58717 USPATFULL
TITLE: Thrombomodulin Derivatives and Conjugates
INVENTOR(S): Chaikof, Elliot L., Atlanta, GA, UNITED STATES
Cazalis, Chrystelle S., Pessac, FRANCE
Haller, Carolyn A., Atlanta, GA, UNITED STATES
PATENT ASSIGNEE(S): EMORY UNIVERSITY, Atlanta, GA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080051562	A1	20080228
APPLICATION INFO.:	US 2005-598149	A1	20050222 (10)
	WO 2005-US5554		20050222
			20070417 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-546436P	20040220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER AND SULLIVAN P C, 4875 PEARL EAST CIRCLE, SUITE 200, BOULDER, CO, 80301, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 208 USPATFULL on STN

TI Unstructured recombinant polymers and uses thereof

AB The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:44718 USPATFULL

TITLE: Unstructured recombinant polymers and uses thereof

INVENTOR(S): Schellenberger, Volker, Palo Alto, CA, UNITED STATES
Stemmer, Willem P., Los Gatos, CA, UNITED STATES
Wang, Chia-wei, Santa Clara, CA, UNITED STATES
Scholle, Michael D., Mountain View, CA, UNITED STATES
Popkov, Mikhail, San Diego, CA, UNITED STATES
Gordon, Nathaniel C., Campbell, CA, UNITED STATES
Cramer, Andreas, Los Altos Hills, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080039341	A1	20080214
APPLICATION INFO.:	US 2007-715276	A1	20070306 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2006-528927, filed on 27 Sep 2006, PENDING Continuation-in-part of Ser. No. US 2006-528950, filed on 27 Sep 2006, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-721270P	20050927 (60)
	US 2005-721188P	20050927 (60)
	US 2006-743622P	20060321 (60)
	US 2006-743410P	20060306 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US

NUMBER OF CLAIMS: 49

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 47 Drawing Page(s)

LINE COUNT: 8692

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 208 USPATFULL on STN

TI NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

AB This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute

coronary syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:23784 USPATFULL
TITLE: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN
FUSION PROTEINS AS ANTICOAGULANTS
INVENTOR(S): Light, David, San Mateo, CA, UNITED STATES
McLean, Kirk, Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Bayer Schering AG (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080020965	A1	20080124
APPLICATION INFO.:	US 2007-766160	A1	20070621 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-427805, filed on 30 Apr 2003, GRANTED, Pat. No. US 7250168		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376566P	20020501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 1100 13th STREET, N.W., SUITE 1200, WASHINGTON, DC, 20005-4051, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2251	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 208 USPATFULL on STN

TI NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

AB This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:22809 USPATFULL
TITLE: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN
FUSION PROTEINS AS ANTICOAGULANTS
INVENTOR(S): Light, David, San Mateo, CA, UNITED STATES
McLean, Kirk, Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Bayer Schering AG (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080019985	A1	20080124
APPLICATION INFO.:	US 2007-766155	A1	20070621 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-427805, filed on 30 Apr 2003, GRANTED, Pat. No. US 7250168		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376566P	20020501 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, LTD., 1100 13th STREET, N.W., SUITE 1200, WASHINGTON, DC, 20005-4051, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2259	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 14 OF 208 USPATFULL on STN

TI Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney

AB The present invention provides novel polynucleotides encoding HGPRBMY23 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY23 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly renal diseases and/or disorders, colon cancer, breast cancer, and diseases and disorders related to aberrant NFKB modulation. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:16937 USPATFULL

TITLE: Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney

INVENTOR(S): Barber, Lauren E., Higganum, CT, UNITED STATES
Cacace, Angela, Durham, CT, UNITED STATES
Feder, John N ., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Ringoes, NJ, UNITED STATES
Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
Neubauer, Michael G., Skillman, NJ, UNITED STATES
Kornacker, Michael G., Princeton, NJ, UNITED STATES

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080014593	A1	20080117
APPLICATION INFO.:	US 2007-897997	A1	20070831 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-375157, filed on 26 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2001-10568, filed on 7 Dec 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251926P	20001207 (60)
	US 2001-269795P	20010214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1-26	

NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 14355
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 208 USPATFULL on STN

TI Inhibitors of TNF α , PDE4 and B-RAF, compositions thereof and methods of use therewith

AB Provided herein are compounds having TNF α and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula I: ##STR1##

and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R^{sup.1}, R^{sup.2}, R^{sup.3}, R^{sup.4}, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNF α and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNF α and/or PDE4 and/or B-RAF inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:5093 USPATFULL

TITLE: Inhibitors of TNF α , PDE4 and B-RAF, compositions thereof and methods of use therewith

INVENTOR(S): McKenna, Jeffrey M., Horsham, UNITED KINGDOM
Papa, Patrick W., Carlsbad, CA, UNITED STATES
Sakata, Steven T., San Diego, CA, UNITED STATES
Erdman, Paul E., San Diego, CA, UNITED STATES
Packard, Garrick K., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080004271	A1	20080103
APPLICATION INFO.:	US 2007-654344	A1	20070116 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-759819P	20060117 (60)
	US 2006-814862P	20060619 (60)
	US 2006-818246P	20060630 (60)
	US 2006-854637P	20061025 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

LINE COUNT: 10585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:17:41 ON 15 SEP 2008)

FILE 'MEDLINE, USPATFULL, DGENE, BIOSIS' ENTERED AT 15:18:37 ON 15 SEP 2008

L1 824 S THROMBOMODULIN AND POLYMER
L2 0 S (TRUNCATED THROMBOMODULIN CONJUGATE)
L3 0 S L1 AND (CONJUGATE THROMBOMODULIN)

L4 1 S (THROMBOMODULIN CONJUGATE)
L5 29925 S (CARBOXY TERMINUS)

FILE 'BIOSIS, EMBASE, USPATFULL, WPIDS, BIOTECHDS, MEDLINE, SCISEARCH'
ENTERED AT 15:32:57 ON 15 SEP 2008

E HALLER, C/AU

E CAZALIS, C/AU

E CHAIKOF, E/AU

L6 0 S (THROMOBOMODULIN AND PEG)
L7 208 S (THROMBOMODULIN AND PEGYLATED)
L8 1 S L7 AND (GGM)
L9 1 S L7 AND (EGF4-6)

=>